Prevalence and Management of Chronic Kidney Disease in Irish Primary Care Network
Preprint
Abstract
Background: Chronic kidney disease (CKD) imposes a substantial burden on health systems and society. Although early detection and guideline-recommended management can improve outcomes, opportunities remain to enhance management in primary care. Aim: To evaluate CKD prevalence, guideline-directed medical therapy (GDMT), and monitoring in Irish primary care. Design and Setting: Retrospective cohort study using community-based electronic health records (EHR) from the CRADLE database, across 66 Irish practices. Methods: Active adults aged ≥20 years on 30 July 2025 were included. CKD prevalence was determined using estimated glomerular filtration rate (eGFR) and/or urine albumin-to-creatinine ratio (uACR). Descriptive analyses of epidemiology, prescribing, and monitoring were conducted. Results: Of 468,534 adults, 19,382 met the criteria of laboratory-confirmed CKD: age- and sex-standardised prevalence was 5.36%. 74.0% of laboratory-confirmed CKD patients have ≥1 cardiometabolic comorbidities. Within 12 months of laboratory-confirmed CKD, monitoring increased over time, with 66.0% of patients receiving follow-up eGFR test and 15.1% receiving uACR test, falling to 6.6% among patients without type 2 diabetes (T2DM). Among GDMT-eligible CKD patients, 64.0% received any renin-angiotensin-aldosterone inhibitors (RAASi) and 30.9% received any sodium-glucose cotransporter 2 inhibitors (SGLT2i) after they met their prescription eligibility for CKD, but SGLT2i use dropped to 9.4% among those without T2DM or heart failure. Conclusion: CKD and cardiometabolic comorbidities impose a substantial burden in Irish primary care. Despite improved kidney function testing, albuminuria testing remained low, particularly in non-diabetic patients, and GDMT use was suboptimal. Improving albuminuria testing and timely GDMT offers important opportunities to improve CKD outcomes in Irish primary care.Keywords
This publication has 16 references indexed in Scilit:
- SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and AlbuminuriaJAMA, 2026
- Impact of Improved Diagnosis and Treatment on Holistic CKD BurdenKidney International Reports, 2025
- Prevalence and determinants of chronic kidney disease among community-dwelling adults, 50 years and older in IrelandClinical Kidney Journal, 2025
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney DiseaseJAMA Network Open, 2023
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisEuropean Heart Journal, 2021
- Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines AgencyAmerican Journal of Kidney Diseases, 2020
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2019
- Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical TrialsAmerican Journal of Kidney Diseases, 2016
- Prevalence of diminished kidney function in a representative sample of middle and older age adults in the Irish populationBMC Nephrology, 2012